A leading cancer surgeon has described Ferring's new prostate cancer drug degarelix, as a "breakthrough" on the basis of fresh Phase III results.
The annual European Association of Urology Congress in Milan heard how the medicine lowered levels of testosterone in prostate cancer patient almost as effectively as surgical castration, the treatment of last resort. The drug, an injectable gonadotropin-releasing hormone antagonist, was also shown to drive down levels of the male hormone immediately, unlike currently available treatments.
"Our goal is always to have a fast and sustained reduction in testosterone levels" said John Anderson, a consultant urological surgeon at the Royal Hallamshire Hospital in Sheffield, UK. "This new data shows that degarelix produced an extremely rapid impact, approaching the immediacy of surgery."
Read full story at The National Prostate Coalition.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment